Decitabine (NCT06561074)

Name: Decitabine trial for T-cell Acute Lymphoblastic Leukemia (NCT06561074)
Uploaded: 2026-10-31T22:27:53.756Z
Duration: 1 min 21 s
Description: Decitabine trial for T-cell Acute Lymphoblastic Leukemia (NCT06561074). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06561074.

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy): a one-minute explainerNCT065610741 min

Decitabine trial for T-cell Acute Lymphoblastic Leukemia (NCT06561074). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for patients aged one month through 21 years with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.

The idea: combine intravenous calaspargase pegol and decitabine with oral venetoclax. Calaspargase removes asparagine needed to make proteins; venetoclax blocks a survival protein. Decitabine alters DNA methylation. Researchers assess responses and safety, and how many patients can proceed to stem-cell transplant. Transplant is not required for everyone.

This phase 2 study plans 22 patients. David McCall leads it at MD Anderson in Houston, the single recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.